All In Biotech

NDA 209885 · Teva Branded Pharm

Austedo

Deutetrabenazine · Oral

Breakthrough therapyPriority review

Last checked: Nov 20, 2026Latest source record: Aug 30, 2017 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2017

Aug 30, 2017

Approved uses

1

Original approval plus efficacy supplements

Registered trials

18

11 Phase 3, 2 recruiting

FAERS reports

5,937

2,709 serious, 498 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

No structured label for this application in openFDA. Older and discontinued products often have none.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Aug 30, 2017 Original approval · Type 9 - New Indication Submitted as Distinct NDA, Consolidated with Original NDA after Approval · priority review Breakthrough therapyLabelLetterReview
3 products under this application
  • AUSTEDO · DEUTETRABENAZINE 12MG · TABLET, ORAL · Prescription
  • AUSTEDO · DEUTETRABENAZINE 6MG · TABLET, ORAL · Prescription
  • AUSTEDO · DEUTETRABENAZINE 9MG · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Deutetrabenazine" as an intervention, any sponsor and status, largest first.

All 18 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective778
  • death435
  • depression388
  • dyskinesia386
  • tremor294
  • product use issue280
  • somnolence271
  • suicidal ideation260
  • fall255
  • insomnia255
  • product use in unapproved indication255
  • fatigue248

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20161
201786
2018405
2019601
2020708
2021778
2022527
2023503
2024950
2025780
2026598

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Austedo (Deutetrabenazine)

2024 spending

$1.07B

Beneficiaries

18,418

162,212 claims

Per beneficiary

$57,927

$103.14 per unit

View as table
YearSpending
2020$530,460,830
2021$666,002,295
2022$890,369,750
2023$1,123,439,045
2024$1,066,901,471

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 31 on PubMed

Sponsor: Teva

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.